News Alnylam Pharmaceuticals, Inc.

Stocks

ALNY

US02043Q1076

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-06-10 pm EDT			5-day change	1st Jan Change
291.22 ^USD	-2.17%		-0.46%	-26.76%

08:10am	Alnylam, Genesis Pharma Expand Commercial Partnership Into 4 Nordic Markets	MT
Jun. 09	Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 11:20 AM

All News

Mentions Relevance

08:10am	Alnylam, Genesis Pharma Expand Commercial Partnership Into 4 Nordic Markets	MT
Jun. 09	Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 11:20 AM
Jun. 03	Alnylam, Inceptive sign up to $2 billion AI drug discovery deal	RE
Jun. 03	Alnylam Pharmaceuticals Strikes Up to $2 Billion AI Collaboration With Inceptive Nucleics	MT
Jun. 03	Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics	BU
Jun. 03	Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics	CI
May. 27	Alnylam Pharmaceuticals, Inc. Elects Benjamin F. Cravatt as Class III Director and Member of Board?s Science and Technology Committee, Effective as of June 1, 2026	CI
May. 19	Alnylam Issues 2025 Corporate Responsibility Report	BU
May. 19	Alnylam Pharmaceuticals : 2025 REPORT	PU
May. 13	Alnylam Pharmaceuticals, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 10:40 AM
May. 12	Alnylam Pharmaceuticals, Inc. Announces New Analyses from the Helios-B Phase 3 Study of Vutrisiran in Patients	CI
May. 12	New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden	BU
May. 07	Alnylam to Webcast Presentations at Upcoming Investor Conferences	BU
May. 04	Alnylam Pharmaceuticals : Q1 2026 Presentation ›	PU
May. 04	Alnylam Pharmaceuticals : Q1 2026 GAAP/Non-GAAP Reconciliation ›	PU
May. 04	Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM	BU
May. 01	RBC Trims Price Target on Alnylam Pharmaceuticals to $445 From $450, Keeps Outperform Rating	MT
Apr. 30	Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 30	Alnylam Pharmaceuticals, Inc., Q1 2026 Earnings Call, Apr 30, 2026
Apr. 30	Alnylam Pharmaceuticals Q1 Adjusted Net Income, Revenue Rise; Reiterates 2026 Product Revenue Guidance -- Shares Up Pre-Bell	MT
Apr. 30	(ALNY) Alnylam Pharmaceuticals Expects 2026 Total Net Product Revenue Range $4.90B - $5.30B	MT
Apr. 30	Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Reports Q1 Revenue $1.17B, vs. FactSet Est of $1.12B	MT
Apr. 30	Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $1.99 per Share	MT
Apr. 30	Alnylam: Q1 Earnings Snapshot	AQ
Apr. 30	Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress	BU